|
2026 Journal Article Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 <scp>ALLG MM23</scp> ( <scp>SeaLAND</scp> ) trialRees, Matthew J., Lasica, Masa, Kalff, Anna, Low, Michael, Harrup, Rosemary, Lai, Hock Choong, Sidiqi, M. Hasib, Doo, Nicole Wong, Routledge, David, Hocking, Jay, Campbell, Philip, Heenan, Jessica, Horvath, Noemi, Chien, Nicole, Renwick, William E. P., McCaughan, Georgia, Eek, Richard, Lenton, Douglas S., Wright, Tricia, Gazdar, Sher Gul, Mazumdar, Deepmala, Butcher, Belinda, Mollee, Peter, Quach, Hang and the Australasian Leukaemia and Lymphoma Group (2026). Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 ( SeaLAND ) trial. British Journal of Haematology bjh.70851. doi: 10.1111/bjh.70851 |
|
2026 Journal Article Toxicity‐related treatment cessation in newly diagnosed multiple myeloma—risk factors and survival: an analysis from the APAC and ANZ Myeloma and Related Diseases RegistryLee, Ji Hyun, Kim, Sung‐Hyun, Kim, Kihyun, Ashrafi, Elham, Wellard, Cameron, Moore, Elizabeth, Chng, Wee Joo, Chen, Wenming, Gan, Gin Gin, Ho, Phoebe Joy, Mollee, Peter, Quach, Hang, Harrison, Simon, McDonald, Emma J. and Spencer, Andrew (2026). Toxicity‐related treatment cessation in newly diagnosed multiple myeloma—risk factors and survival: an analysis from the APAC and ANZ Myeloma and Related Diseases Registry. European Journal of Haematology ejh.70318. doi: 10.1111/ejh.70318 |
|
2026 Journal Article LBA-16 Relationships Between Quality of Life, Bone Pain, Fatigue and Disease Symptoms, and Physical Activity, Neuromuscular Strength and Fitness, in People With Multiple MyelomaNicol, Jennifer L., Chong, Jamie E., Cunningham, Brent, Woodrow, Carmel, King, Tracy, Beck, Belinda, Kay, Shelley, McDonald, Michelle, Carter, Daniel, Beer, Hayley, Mollee, Peter, Weber, Nicholas, Nicol, Andrew, Hill, Michelle, Hart, Nicolas and Skinner, Tina (2026). LBA-16 Relationships Between Quality of Life, Bone Pain, Fatigue and Disease Symptoms, and Physical Activity, Neuromuscular Strength and Fitness, in People With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 26, S381. doi: 10.1016/s2152-2650(26)03942-x |
|
2026 Journal Article Impact of socioeconomic status on treatment and survival in multiple myeloma in AustraliaGration, Betty, Wellard, Cameron, Moore, Elizabeth, Mollee, Peter, Shetty, Anita, Forsyth, Cecily, Heenan, Jessica, Kerridge, Ian, McQuilten, Zoe, Wood, Erica, Spencer, Andrew and McCaughan, Georgia (2026). Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia. Blood Cancer Journal. doi: 10.1038/s41408-026-01596-7 |
|
2026 Journal Article Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases RegistryLim, Kenneth J. C., Ashrafi, Elham, Wellard, Cameron, Moore, Elizabeth M., Gration, Betty, Augustson, Bradley, Mollee, Peter, Zhang, Jennifer, Doo, Nicole Wong, Dun, Karen, Cooke, Rachel, Ringkowski, Sabine, Bryant, Adam, McCaughan, Georgia, Wood, Erica, McQuilten, Zoe, Ho, P. Joy, Quach, Hang and Spencer, Andrew (2026). Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry. British Journal of Haematology, 209 (2) bjh.70609, 764-768. doi: 10.1111/bjh.70609 |
|
2026 Journal Article A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myelomaLee, Hans C., Plattel, Wouter J., Harrison, Simon J., Sborov, Douglas W., Lentzsch, Suzanne, Spencer, Andrew, Niesvizky, Ruben, Trudel, Suzanne, Mollee, Peter, Vij, Ravi, Minnema, Monique C., Rasche, Leo, Upreti, Vijay V., Zhou, Di, Xia, Qing, Talpes, Mihaela, Eggert, Tobias, Kapoor, Prashant and Ailawadhi, Sikander (2026). A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma. Blood, 148 (2) blood.2025032044, 199-212. doi: 10.1182/blood.2025032044 |
|
2026 Journal Article Cytogenetic testing in newly diagnosed multiple myeloma: real world evidence on clinical features and adverse outcomes for high risk groupsZammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Wellard, Cameron, Ashrafi, Elham, Sidiqi, Hasib, Lim, Kenneth J. C., Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Harrison, Simon, Ho, P Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rajagopal, Rajeev, Rosengarten, Brian, Wood, Erica, McQuilten, Zoe and Spencer, Andrew (2026). Cytogenetic testing in newly diagnosed multiple myeloma: real world evidence on clinical features and adverse outcomes for high risk groups. Clinical Lymphoma Myeloma and Leukemia, 26 (4), e492-e501.e1. doi: 10.1016/j.clml.2025.12.005 |
|
2026 Journal Article Comparative evaluation of free light chain assays in AL amyloidosis: performance of Sebia versus Freelite and N-LatexZhao, Frances, Pretorius, Carel and Mollee, Peter (2026). Comparative evaluation of free light chain assays in AL amyloidosis: performance of Sebia versus Freelite and N-Latex. Practical Laboratory Medicine, 49 e00519, 1-7. doi: 10.1016/j.plabm.2026.e00519 |
|
2026 Journal Article An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapyGibbons, Anthea, Chakravorty, Lipi, Sidiqi, Hasib, Ting, Stephen, Kwok, Fiona, Wisniowski, Brendan, Ranjit Anderson, Nirija, Korczyk, Dariusz, Motorna, Olga and Mollee, Peter (2026). An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy. Internal Medicine Journal, 56 (4) imj.70335, 582-588. doi: 10.1111/imj.70335 |
|
2026 Journal Article An individualised exercise intervention improves health outcomes for people with multiple myeloma: The Myeex randomised waitlist-controlled trialSkinner, Tina, Nicol, Jenny, Cunningham, Brent, Woodrow, Carmel, Adlard, Kirsten, Mollee, Peter, Weber, Nicholas, Robinson, Harley, Okano, Satomi, Stoll, Thomas, Hartel, Gunter, Nicol, Andrew and Hill, Michelle (2026). An individualised exercise intervention improves health outcomes for people with multiple myeloma: The Myeex randomised waitlist-controlled trial. Journal of Clinical Exercise Physiology, 15 (s2), 252-252. doi: 10.31189/2165-7629-15-s2.252 |
|
2026 Journal Article Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupSim, Shirlene, McCaughan, Georgia, Zannettino, Andrew, Ho, P. Joy, Joshua, Douglas, Talaulikar, Dipti, Mollee, Peter, Prince, H. Miles, Spencer, Andrew, Harrison, Simon, Lee, Cindy, Augustson, Bradley, Kalff, Anna, Ling, Silvia, Weber, Nicholas, Yong, Angelina and Quach, Hang (2026). Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 56 (3) imj.70329, 457-464. doi: 10.1111/imj.70329 |
|
2026 Journal Article Wild-type transthyretin-related amyloidosis in kindreds: a play of chance or new epiphenomenon?Kang, Katherine, Mollee, Peter, Booth, David and Korczyk, Dariusz (2026). Wild-type transthyretin-related amyloidosis in kindreds: a play of chance or new epiphenomenon?. Heart, Lung and Circulation, 35 (3). doi: 10.1016/j.hlc.2025.06.1038 |
|
2026 Journal Article Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant ineligible patients receiving first-line VRd, Rd and VCd: Results from the Australian and New Zealand Myeloma and Related Diseases RegistryZhao, Sarah, Wellard, Cameron, Moore, Elizabeth M., Spencer, Andrew, Quach, Hang, Ho, P. Joy, McDonald, Emma-Jane, Mollee, Peter, Harrison, Simon J., Augustson, Bradley, Wood, Erica M., McQuilten, Zoe K. and Rajagopal, Rajeev (2026). Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant ineligible patients receiving first-line VRd, Rd and VCd: Results from the Australian and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma Myeloma and Leukemia, 26 (1), 49-56. doi: 10.1016/j.clml.2025.08.004 |
|
2026 Journal Article A post-market economic evaluation of bortezomib, lenalidomide and dexamethasone versus pre-funding standard of care for newly diagnosed multiple myeloma using registry dataIrving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew and McQuilten, Zoe K. (2026). A post-market economic evaluation of bortezomib, lenalidomide and dexamethasone versus pre-funding standard of care for newly diagnosed multiple myeloma using registry data. PharmacoEconomics, 44 (1), 83-95. doi: 10.1007/s40273-025-01554-4 |
|
2025 Conference Publication Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)Lim, Sueh-Li, Reynolds, John, Pemberton, Lucy, Wright, Tricia, Lee, Sophie, Mollee, Peter, Shetty, Anita C., Kim, Yu Jin, Helen, Weston, Nina, Byard, Le, Khoa, McQuilten, Zoe, Quach, Hang and Spencer, Andrew (2025). Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22). 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-5842 |
|
2025 Conference Publication Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosisChakraborty, Rajshekhar, Kastritis, Efstathios, Huart, Antoine, Jaccard, Arnaud, Landau, Heather, Iida, Shinsuke, Motorna, Olga, Mollee, Peter, Ishida, Tadao, Kawano, Yawara, Bhutani, Manisha, D'Souza, Anita, Cowan, Andrew, Hoffman, James, Talati, Chetasi, Rosenberg, Tanya, La Motte-Mohs, Ross, Wang, Fan, Hoffman, David, Fei, Mingwei, Arriola, Emma, Yu, Jovian, Kumar, Shaji, Dispenzieri, Angela, Palladini, Giovanni and Sanchorawala, Vaishali (2025). Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis. 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-692 |
|
2025 Conference Publication Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)Rees, Matthew, Lasica, Masa, Kalff, Anna, Low, Michael, Harrup, Rosemary, Lai, Hock Choong, Sidiqi, M Hasib, Wong Doo, Nicole, Routledge, David, Hocking, Jay, Campbell, Philip, Heenan, Jessica, Horvath, Noemi, Chien, Nicole, Renwick, William, McCaughan, Georgia, Eek, Richard, Lenton, Douglas, Gazdar, Sher Gul, Mazumdar, Deepmala, Butcher, Belinda, Mollee, Peter and Quach, Hang (2025). Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND). 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-4039 |
|
2025 Conference Publication Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groupsZammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Sidiqi, M Hasib, Wellard, Cameron, Ashrafi, Elham, Harrison, Simon, Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Ho, Phoebe Joy, King, Tracy, Mollee, Peter, Quach, Hang, Rajagopal, Rajeev, McQuilten, Zoe, Wood, Erica, Rosengarten, Brian and Spencer, Andrew (2025). Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups. 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-2221 |
|
2025 Journal Article A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of AmyloidosisSanchorawala, Vaishali, Wechalekar, Ashutosh, Mollee, Peter, Sekijima, Yoshiki, Maurer, Mathew S., Leung, Nelson, Schönland, Stefan O. and Kumar, Shaji (2025). A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis. Amyloid, 32 (4), 1-6. doi: 10.1080/13506129.2025.2570096 |
|
2025 Journal Article Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaMcCaughan, Georgia, Beer, Hayley, Bryant, Christian, Ho, P. Joy, King, Tracy, Lee, Cindy, Mollee, Peter, Prince, H. Miles, Spencer, Andrew, Talaulikar, Dipti, Vandyke, Kate, Weber, Nicholas, Yong, Angelina, Harrison, Simon and Quach, Hang (2025). Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Internal Medicine Journal, 55 (10) imj.70148, 1741-1751. doi: 10.1111/imj.70148 |
